...
首页> 外文期刊>Bioorganic and Medicinal Chemistry >Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor.
【24h】

Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor.

机译:直接观察(NMR)胰高血糖素受体拮抗剂在表达人胰高血糖素受体的鼠肝中的功效。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The demonstration of pharmacodynamic efficacy of novel chemical entities represents a formidable challenge in the early exploration of synthetic lead classes. Here, we demonstrate a technique to validate the biological efficacy of novel antagonists of the human glucagon receptor (hGCGR) in the surgically removed perfused liver prior to the optimization of the pharmacokinetic properties of the compounds. The technique involves the direct observation by (13)C NMR of the biosynthesis of [(13)C]glycogen from [(13)C]pyruvate via the gluconeogenic pathway. The rapid breakdown of [(13)C]glycogen (glycogenolysis) following the addition of 50 pM exogenous glucagon is then monitored in real time in the perfused liver by (13)C NMR. The concentration-dependent inhibition of glucagon-mediated glycogenolysis is demonstrated for both the peptidyl glucagon receptor antagonist 1 and structurally diverse synthetic antagonists 2-7. Perfused livers were obtained from a transgenic mouse strain that exclusively expresses the functional human glucagon receptor, conferring human relevance to the activity observed with glucagon receptor antagonists. This technique does not provide adequate quantitative precision for the comparative ranking of active compounds, but does afford physiological evidence of efficacy in the early development of a chemical series of antagonists.
机译:在合成铅类的早期探索中,新型化学实体的药效学功效证明是一个巨大的挑战。在这里,我们展示了一种在优化化合物药代动力学特性之前,通过手术切除的灌注肝脏验证人胰高血糖素受体(hGCGR)新型拮抗剂的生物学功效的技术。该技术涉及通过(13)C NMR直接观察通过糖原异生途径从[(13)C]丙酮酸中合成[[13] C]糖原的过程。然后通过(13)C NMR在灌注肝脏中实时监测添加50 pM外源胰高血糖素后[[(13)C]糖原的快速分解(糖原分解)。肽基胰高血糖素受体拮抗剂1和结构多样的合成拮抗剂2-7均证明了胰高血糖素介导的糖原分解的浓度依赖性抑制。从仅表达功能性人胰高血糖素受体的转基因小鼠品系获得灌注肝脏,从而赋予人与胰高血糖素受体拮抗剂所观察到的活性的相关性。该技术不能为活性化合物的比较分级提供足够的定量精度,但是确实提供了在化学系列拮抗剂的早期开发中功效的生理证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号